Eating Disorders and GLP-1 RAs

PDF Available ?

Yes

Year

2025

Glucagon-like peptide-1receptor agonists (GLP-1 RAs), such as semaglutide (Ozempic), are medications
originally developed to treat type 2 diabetes. GLP-1 RAs are now being used as an approved or off-label treatment for weight loss and have been trialled as a treatment for some eating disorders such as binge eating disorder (BED).

There is limited research available to help researchers, clinicians and patients/consumers to understand 
the relationships between GLP-1 RAs and eating disorders. However, it is thought that GLP-1 RAs may 
negatively impact eating disorder symptomology and treatment in a number of ways.

This factsheet provides information about GLP-1 RAs as well as their possible interaction with eating disorders including physical and psychological impacts. Practice points are provided for clinicians.


« Back to Browse Resources

See also

NEDC and Beyond Blue - Eating disorders, anxiety and depression

A person with an eating disorder will often be diagnosed with another mental health problem.

Read more

AED Eating Disorders: A Guide to Medical Care (4th Ed.)

Often referred to as, the purple book, this guide from the Academy for Eating Disorders' (AED) Medical Care Standards Committee, is intended as a resource to promote recognition and risk management in the care of those with eating disorders.

Read more

Early detection of eating disorders in general practice

The aim of this article was to heighten awareness of the role of early identification and diagnosis of eating disorders, especially anorexia nervosa and bulimia nervosa, in the primary care setting.

Read more

Issue 62 I Comorbid Diabetes and Eating Disorders

NEDC e-Bulletin Editor’s NoteIn our work and training across the country, the National Eating Disorders Collaboration has seen an increasing interest in the topic of eating disorders and co-occurring diabetes.

Read more